Overview

Platine, Avastin and OLAparib in 1st Line

Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
Phase:
Phase 3
Details
Lead Sponsor:
Arcagy Research
ARCAGY/ GINECO GROUP
Collaborators:
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Arbeitsgemeinschaft Gynaekologishe Onkologie Germany
Belgian Gynaecological Oncology Group
Grupo Español de Investigación en Cáncer de Ovario
Gynecologic Oncology Trial & Investigation Consortium
Mario Negri Gynecologic Oncology
Mario Negri Gynecologic Oncology group (MaNGO)
Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies
Nordic Society for Gynaecologic Oncology
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Treatments:
Olaparib